Menu
No results found.
Weekly Share Price & Valuation Overview
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions worldwide. The company offers patient monitoring and life support products, such as monitors, ventilators, defibrillators systems, anesthesia machines, operating tables, surgical lights, suspension towers, infusion pumps, electrocardiographs, operating room and intensive care unit solutions, ultrasound, radiology, AED, CLIA, medical supply units, orthopedics, obstretrics, gynecology,, cardiovascular intervention, animal medical, and artema GAS module and accessories, as well as emergency care, perioperative care, critical care, and IT solutions. It also provides a series of instruments and solutions for life information monitoring and support, as well as a series of minimally invasive surgical products, including surgical laparoscopic camera systems, cold light sources, pneumoperitoneum machines, optical endoscopes, ultrasonic scalpels, energy platforms, minimally invasive surgical instruments and consumables. In addition, the company offers in-vitro diagnostics products, including hematology analyzers and reagents, micro plate readers and washers coagulation, and microbiology solutions; medical imaging systems comprising ultrasound and radiology products; and veterinary products, as well as chemiluminescence immunoassay analyzers, blood cell analyzers, biochemical analyzers, coagulation analyzers, urine analyzers, microbial diagnostic systems, glycated hemoglobin analyzers, and related reagents, which obtain clinical diagnostic information through testing of human samples, such as blood, body fluids, tissues, etc. The company was founded in 1991 and is headquartered in Shenzhen, the People's Republic of China.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROE ≥15% reflects strong returns on shareholder equity.
- ROA ≥7% shows efficient use of assets.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 285.20B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 272.52B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 35.59B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 22.09B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY 13.26B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 29.38
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 9.20
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 3.26%
- Shares Outstanding
- 1.21B
- Float Shares
- 519.16M
- Implied Shares Outstanding
- 1.21B
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
34.40%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
37.25%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
62.08%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
31.29%
- ROA Strong Return on assets: net income ÷ total assets.
-
13.55%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
28.18%
- Revenue Growth Year-over-year revenue growth.
-
-12.10%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-16.80%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-16.80%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.99
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.69
- Total Cash Cash and equivalents.
- CNY 17.71B
- Total Debt Short + long-term interest-bearing debt.
- CNY 300.28M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CNY -17.41B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.02
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY 11.06B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY 5.35B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
31.08%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
15.02%
- Cash Conversion (OpCF/EBITDA)
- 0.83
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.